[Clinical evaluation of 30 mg cinnoxicam in patients with osteoarthrosis. Double blind controlled trial].
We tested the therapeutic response of osteoarthrosis subjects to 30 mg piroxicam cinnamate (Sinartrol). The double-blind study was conducted in 2 homogeneous groups of 30 patients each treated with piroxicam cinnamate one 30-mg tablet twice daily for 2 days followed by 1 tablet daily for further 13 days and with piroxicam cinnamate 20 mg tablets (according to the same posologic scheme) respectively. The results obtained demonstrate the efficacy of this new piroxicam cinnamate formulation which led to a significant clinical improvement, already evident after 2 days of treatment and even more evident at the end of therapy. Patients compliance to treatment was good and side effects were scarce and spontaneously subsiding.
Peretti
G
G
Divisione Ortopedia e Traumatologia, Ospedale San Gerardo-Monza (Milano).
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy* / Q000503:physiopathology; D010894:Piroxicam / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; C057291:piroxicam cinnamate
Valutazione clinica del cinnoxicam 30 mg in pazienti affetti da osteoartrosi. Studio controllato in doppio cieco.